Programmes

Amura's main research focus is the exploitation of the AMcore™ technology for the selective inhibition of CAC1 proteases. 

Amura also has exclusive commericial and intellectual property rights to a broad spectrum ß-lactamase inhibitors (AM-112). This is an ideal protective combination product for otherwise resistance susceptible b-lactam antibiotics.

For more information on the Amura programmes, please use the sub-menus within the navigation pane on the left.

A molecular model of an Amura AMcore™ bicyclic inhibitor (ex WO2008007127) in the active site of cathepsin K